- Home
- ICUI vs MLTX Comparison
ICUI vs MLTX Comparison
Compare ICUI & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUI
- MLTX
- Stock Information
- Founded
- ICUI 1984
- MLTX 2021
- Country
- ICUI United States
- MLTX Switzerland
- Employees
- ICUI N/A
- MLTX N/A
- Industry
- ICUI Medical/Dental Instruments
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICUI Health Care
- MLTX Health Care
- Exchange
- ICUI Nasdaq
- MLTX Nasdaq
- Market Cap
- ICUI 3.0B
- MLTX 2.8B
- IPO Year
- ICUI 1992
- MLTX N/A
- Fundamental
- Price
- ICUI $128.18
- MLTX $55.89
- Analyst Decision
- ICUI Buy
- MLTX Strong Buy
- Analyst Count
- ICUI 6
- MLTX 7
- Target Price
- ICUI $185.00
- MLTX $74.83
- AVG Volume (30 Days)
- ICUI 371.2K
- MLTX 457.7K
- Earning Date
- ICUI 08-07-2025
- MLTX 08-05-2025
- Dividend Yield
- ICUI N/A
- MLTX N/A
- EPS Growth
- ICUI N/A
- MLTX N/A
- EPS
- ICUI N/A
- MLTX N/A
- Revenue
- ICUI $2,372,504,000.00
- MLTX N/A
- Revenue This Year
- ICUI N/A
- MLTX N/A
- Revenue Next Year
- ICUI N/A
- MLTX N/A
- P/E Ratio
- ICUI N/A
- MLTX N/A
- Revenue Growth
- ICUI 2.96
- MLTX N/A
- 52 Week Low
- ICUI $107.00
- MLTX $31.42
- 52 Week High
- ICUI $196.26
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- ICUI 55.51
- MLTX 62.07
- Support Level
- ICUI $120.95
- MLTX $52.02
- Resistance Level
- ICUI $125.02
- MLTX $55.81
- Average True Range (ATR)
- ICUI 5.30
- MLTX 1.83
- MACD
- ICUI 1.12
- MLTX -0.09
- Stochastic Oscillator
- ICUI 82.93
- MLTX 95.44
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.